News stories about ObsEva (NASDAQ:OBSV) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ObsEva earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9858090967521 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities research analysts have recently commented on OBSV shares. Zacks Investment Research downgraded ObsEva from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of ObsEva in a research report on Friday, September 8th. Royal Bank of Canada started coverage on ObsEva in a research report on Thursday, September 14th. They set an “outperform” rating and a $22.00 price objective for the company. Finally, Credit Suisse Group started coverage on ObsEva in a research report on Monday, October 9th. They set an “outperform” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $19.00.

Shares of ObsEva (NASDAQ:OBSV) opened at $9.80 on Tuesday. ObsEva has a one year low of $5.00 and a one year high of $14.69.

ObsEva (NASDAQ:OBSV) last announced its earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.01). The business’s revenue was up NaN% on a year-over-year basis. equities analysts forecast that ObsEva will post -2.26 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/19/obseva-obsv-receiving-somewhat-positive-media-coverage-analysis-shows.html.

About ObsEva

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Insider Buying and Selling by Quarter for ObsEva (NASDAQ:OBSV)

Receive News & Stock Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related stocks with our FREE daily email newsletter.